On September 27, 2024, Xuanwu Hospital of Capital Medical University held its 2024 Medical Education and Research Conference. During the event, Baheal Pharma Group and Xuanwu Hospital signed a strategic cooperation agreement to jointly establish the "Xuanwu-Baheal Pharma Neurological Disease Collaborative Innovation Laboratory" and the "Xuanwu-Baheal Pharma Thoracic Disease Joint Laboratory." The collaboration aims to advance cutting-edge medical research and the translation of scientific achievements in key areas such as neuroscience and thoracic surgery. The signing ceremony was attended by Guan Zhongjun, Party Secretary of Xuanwu Hospital, Zhao Guoguang, Deputy Party Secretary and President of Xuanwu Hospital, Fu Gang, Chairman of Baheal Pharma Group, and Song Qing, Director and President of Baheal Pharma Group.

Xuanwu Hospital of Capital Medical University, recognized as the National Medical Center for Neurological Diseases, the National Clinical Research Center for Geriatric Diseases, and the host institution for the China International Neuroscience Institute, shoulders top-tier responsibilities in neurological medical care, education, and research across the nation. It serves as the pioneering base for neuroscience and a cradle for talent cultivation in China, boasting extensive clinical experience, a rich pool of high-level talent, and significant scientific research achievements in the fields of neurological diseases, geriatric medicine, and aging research. The newly established "Xuanwu-Baheal Pharma Neurological Disease Collaborative Innovation Laboratory" aims to become a leading domestic R&D platform. This partnership will leverage Xuanwu Hospital's robust research capabilities and clinical expertise in neuroscience, combined with Baheal Pharma Group's comprehensive innovation incubation system and resource allocation capabilities. The joint lab will focus on uncovering the brain network mechanisms driving neurological diseases, developing Chinese-specific diagnostic and treatment protocols, identifying precise intervention targets, and creating novel diagnostic and therapeutic systems, as well as medical equipment with proprietary Chinese intellectual property. This initiative is set to propel the translation of high-level medical innovations into practical applications.

Additionally, Xuanwu Hospital's Department of Thoracic Surgery is highly regarded for its expert resources, clinical practices, and academic prowess, establishing a solid foundation for collaboration with Baheal Pharma Group. Previously, Baheal played a significant role in the development of Xuanwu Hospital's Integrated Lung Cancer Diagnosis and Treatment Center, advocating for personalized and scientific management throughout the entire course of lung cancer treatment. The establishment of the "Xuanwu-Baheal Pharma Thoracic Disease Joint Laboratory" represents a further integration of both parties' strengths in medical technology, clinical research, and industrial resources. This joint lab will leverage artificial intelligence to advance the development and translation of thoracic surgery navigation devices and early screening and diagnostic reagents for related diseases. The goal is to enhance intelligent management across the full continuum of lung nodule to lung cancer prevention, screening, diagnosis, treatment, and recovery, thus providing patients with safer, more efficient, and precise clinical treatment options.

At the conference, Fu Gang, Chairman of Baheal Pharma Group, was invited as a special guest to deliver a keynote speech titled "Supporting Fundamental Innovation with a Medical Sci-Tech Incubation System." In his address, Fu Gang highlighted several challenges facing China's pharmaceutical industry, including unclear clinical scenarios, a lack of fundamental innovation, and technological blockades at the international level. He emphasized that to achieve breakthroughs in fundamental innovation, it is essential to fully integrate the research and innovation capabilities of national institutions ("national team") with the industrialization and market resources of enterprises. The focus should be on optimizing clinical scenarios, reinforcing basic research, and uncovering fundamental innovations. Efficient resource allocation is crucial to enhance the conversion of scientific research into tangible innovations that genuinely improve medical practices. This, he noted, would create a new productive force in the pharmaceutical industry and significantly benefit patients.

In recent years, under the national strategy to deeply integrate industry, academia, and research while enhancing the conversion and industrialization of scientific and technological achievements, Baheal Pharma Group has consistently accelerated its medical innovation collaborations with national-level research institutions. Leveraging its industry resources and an ecosystem-driven innovation mechanism, Baheal has established multiple joint laboratories and innovation projects with institutions like Peking University Health Science Center, Capital Medical University, Fuwai Hospital, the Chinese Academy of Medical Sciences, and Rehabilitation University. These partnerships aim to uncover clinically valuable innovations from the source. Significant progress has been made in fields such as fully magnetic levitation artificial hearts, medical linear accelerators, electromagnetic-guided biopsy and navigation equipment, nuclear medicine's innovative drugs and SPECT/CT, and novel drugs for oncology and bone regeneration. Beyond the collaborative efforts in research translation, Baheal has also collaborated with Peking University Health Science Center, Peking Union Medical College, and Rehabilitation University to establish multimillion-yuan funds for research translation and education. These initiatives are designed to support medical innovation through diverse measures, including talent development and institutional support.

Looking ahead, Baheal Pharma Group will continue to be guided by actual clinical needs, deepening its collaborations with academic and research institutions. By serving as a catalyst for medical innovation, Baheal aims to facilitate the translation and implementation of more original and leading-edge innovations. Through the power of technological advancements, the company is committed to optimizing medical practices, ultimately enhancing patient care and outcomes.